Coagulation (secondary hemostasis)

Last updated: November 01, 2022

Coagulation (secondary hemostasis)

Watch later

Watch later

Multiple endocrine neoplasia
Seronegative and septic arthritis: Pathology review
Primary sclerosing cholangitis
Papulosquamous and inflammatory skin disorders: Pathology review
Bleeding disorders: Clinical
Nephritic and nephrotic syndromes: Clinical
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review
Aortic dissections and aneurysms: Pathology review
Reactive arthritis
Seronegative arthritis: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Rheumatoid arthritis: Clinical
Systemic lupus erythematosus (SLE): Pathology review
MEN syndromes: Clinical
Leg ulcers: Clinical
Breast cancer: Pathology review
Parkinson disease
Non-Hodgkin lymphoma
Lymphomas: Pathology review
Lymphoma: Clinical
Cushing syndrome
Cushing syndrome: Clinical
Cushing syndrome and Cushing disease: Pathology review
Cirrhosis: Clinical
Physiological changes during exercise
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Thrombotic thrombocytopenic purpura
Thrombocytopenia: Clinical
Hemophilia
Coagulation disorders: Pathology review
Chronic leukemia
Anemia of chronic disease
Peripheral artery disease: Pathology review
Peripheral vascular disease: Clinical
Dermatomyositis
Myalgias and myositis: Pathology review
Hypocalcemia
Hypercalcemia
Hypokalemia
Hypernatremia
Hypernatremia: Clinical
Hyponatremia: Clinical
Hypokalemia: Clinical
Hypomagnesemia
Miscellaneous hypoglycemics
Insulins
Renal artery stenosis
Antiplatelet medications
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Acneiform skin disorders: Pathology review
Staphylococcus aureus
Streptococcus pyogenes (Group A Strep)
Herpes simplex virus
Chronic kidney disease
Vitamin B12 deficiency
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Goodpasture syndrome
Myelodysplastic syndromes
Sjogren syndrome
Sjogren syndrome: Pathology review
Sjogren syndrome: Clinical
Psoriasis
Crohn disease
Acute pyelonephritis
Chronic pyelonephritis
Hypoglycemics: Insulin secretagogues
Gout
Gout and pseudogout: Pathology review
Ulcerative colitis
Inflammatory bowel disease: Clinical
Celiac disease
DNA alkylating medications
Chronic kidney disease: Clinical
Hidradenitis suppurativa
ACE inhibitors, ARBs and direct renin inhibitors
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Bone tumors
Pediatric bone tumors: Clinical
Bone tumors: Pathology review
Developmental dysplasia of the hip
Venous thromboembolism: Clinical
Carpal tunnel syndrome
Heart failure
Thiazide and thiazide-like diuretics
Calcium channel blockers
Adrenergic antagonists: Beta blockers
Positive inotropic medications
Hyperthyroidism
Hyperthyroidism: Pathology review
Lichen planus
Viral hepatitis: Clinical
Hepatitis medications
Viral hepatitis: Pathology review
Autoimmune hepatitis
Pleural effusion: Clinical
Hyperthyroidism medications
Hypothyroidism medications
Rotator cuff tear
Anatomy clinical correlates: Clavicle and shoulder
Breast cancer: Clinical
Osteomalacia and rickets
Pelvic inflammatory disease
Mastocytosis (NORD)
Hernias: Clinical
Abdominal hernias
von Hippel-Lindau disease
PDE5 inhibitors
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Pemphigus vulgaris
Polycystic ovary syndrome
Miscellaneous lipid-lowering medications
Monoclonal antibodies
Osteoarthritis
Rheumatoid arthritis and osteoarthritis: Pathology review
Cytokines
Glucocorticoids
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Platelet disorders: Pathology review
Deep vein thrombosis
Pulmonary embolism
Thrombophlebitis
Opioid agonists, mixed agonist-antagonists and partial agonists
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid antagonists
Anticoagulants: Heparin
Heparin-induced thrombocytopenia
Peripheral artery disease
Focal segmental glomerulosclerosis (NORD)
Minimal change disease
Membranous nephropathy
Poststreptococcal glomerulonephritis
IgA nephropathy (NORD)
Membranoproliferative glomerulonephritis
Rapidly progressive glomerulonephritis
Anticonvulsants and anxiolytics: Benzodiazepines
Diverticulosis and diverticulitis
Sarcoidosis
Acute leukemia
Vasculitis
Primary biliary cholangitis
Hyperkalemia
Jaundice
Stevens-Johnson syndrome
Osteoporosis medications
General anesthetics
Selective serotonin reuptake inhibitors
Systemic lupus erythematosus (SLE): Clinical
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Diabetes insipidus and SIADH: Pathology review
Hepatic encephalopathy
Osteomyelitis
Fibromyalgia
Cell-mediated immunity of natural killer and CD8 cells
Ankylosing spondylitis
Septic arthritis
Hyperparathyroidism
Parathyroid conditions and calcium imbalance: Clinical
Heart failure: Clinical
Cardiomyopathies: Pathology review
Cardiomyopathies: Clinical
Gastrointestinal bleeding: Pathology review
Acute pancreatitis
Pancreatitis: Clinical
Pancreatitis: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Gastroesophageal reflux disease (GERD)
Peptic ulcers and stomach cancer: Clinical
Gastric cancer
Colorectal polyps
Colorectal cancer
Colorectal polyps and cancer: Pathology review
Colorectal cancer: Clinical
Respiratory distress syndrome: Pathology review
Acute respiratory distress syndrome: Clinical
Pediatric infectious rashes: Clinical
Parathyroid disorders and calcium imbalance: Pathology review
Phosphate, calcium and magnesium homeostasis
Obstructive lung diseases: Pathology review
Fever of unknown origin: Clinical
Malabsorption: Clinical
Neurocutaneous disorders: Pathology review
Diabetes mellitus
Diabetes mellitus: Pathology review
Diabetes mellitus: Clinical
Acute kidney injury: Clinical
Neisseria gonorrhoeae
Non-urothelial bladder cancers
Alopecia: Clinical
Esophageal disorders: Clinical
Esophageal disorders: Pathology review
Esophageal surgical conditions: Clinical
Peptic ulcer
Porphyria cutanea tarda
Acute intermittent porphyria
Myocardial infarction
Hypopigmentation skin disorders: Clinical
Subdural hematoma
Alport syndrome
Bullous pemphigoid
Thyroid nodules and thyroid cancer: Clinical
Pheochromocytoma
Kidney stones: Clinical
Asthma: Clinical
Pneumonia: Pathology review
Pneumonia: Clinical
Diarrhea: Clinical
Jaundice: Pathology review
Restrictive lung diseases: Pathology review
Renal failure: Pathology review

Transcript

Watch video only

Hemostasis can be broken down into hemo referring to blood or bleeding and stasis meaning to stop - so together it means stopping bleeding. Hemostasis has two phases: primary and secondary hemostasis.

In primary hemostasis, platelets aggregate to form a plug at the site of an injured blood vessel. While these platelets are aggregating, coagulation, or secondary hemostasis starts.

This is where numerous enzymes that are always floating around in the blood called clotting factors get proteolytically activated, meaning that activation happens when a small piece is chopped off - a bit like pulling the pin out of a grenade.

These factors activate one another, eventually leading to the activation of fibrin or factor Ia. That results in a fibrin mesh which forms around the platelet plug to reinforce it and hold it together.

Without primary and secondary hemostasis, our body would suffer massive blood loss from even the most minor injuries--imagine losing all of your blood volume from something as simple as a pinprick!

So let’s get into the details of secondary hemostasis. The process of forming the fibrin mesh begins via two pathways --the extrinsic and intrinsic pathways.

The intrinsic pathway is called intrinsic because all of the factors required to activate it are intrinsic, or found within the blood.

Conversely, the extrinsic pathway is called extrinsic because it’s activated by tissue factor found extrinsically, or outside of the blood.

Both pathways can become activated independently and ultimately culminate in the activation of factor X, which then proceeds to activate the rest of the coagulation cascade via the common pathway.

Let's start with the extrinsic pathway. It starts when trauma damages the blood vessel, and exposes the cells under the endothelial layer, like smooth muscle cells, which have tissue factor or factor III in their membrane.

Now, it turns out that there’s an enzyme called factor VII floating around in the blood, and some of it is active, meaning that it’s already set to proteolytically cleave other proteins.

When it’s in that state, it’s called active factor VII or VIIa. “a '' for active. Factor VIIa binds to a tissue factor and a calcium ion -which get released by nearby activated platelets--and it forms a VIIa-TF complex on the surface of the smooth muscle cell.

Both the calcium ions and tissue factors are co-factors, meaning that they need to bind to the enzyme factor VIIa to allow it to really get going. This complex then cleaves clotting factor X yielding the active form called factor Xa.

Once factor Xa is generated via the extrinsic pathway, it cleaves factor V into Va and then it uses factor Va and a calcium ion as the cofactors to form the prothrombinase complex which activates prothrombin or factor II, into thrombin or factor IIa.

In fact, each prothrombinase complex can activate thousands of thrombin, so there’s enormous amplification that occurs at this step. Thrombin uses calcium ion as a cofactor and it has a number of pro-coagulative effects.

First, thrombin binds to receptors on platelets causing them to activate. Activated platelets change their shape to form tentacle-like arms that allow them to stick to other platelets.

Second, thrombin activates three cofactors; factor V, which is used in the common pathway; factor VIII; and fabin, which proteolytically cleaves fibrinogen or factor I, into factor Ia or fibrin.

Third, the effect of thrombin on fibrinogen plays a big role. Fibrinogen is soluble in blood, but fibrin isn’t, so fibrin precipitates out of the plasma and forms long protein chains that are like ropes. The fibrin tether platelets to one another, holding the platelet plug together.

Key Takeaways

Coagulation is the process of formation of a blood clot. It is secondary hemostasis that occurs after vascular damage has occurred and platelets have been activated. Its purpose is to form the fibrin mesh necessary to stabilize the platelet plug to stop bleeding. Coagulation happens in a series of steps called the coagulation cascade, which is a series of enzymatic reactions that leads to the conversion of fibrinogen to fibrin. The final product is a stable plug that stops the bleeding. Factors XII, XI, IX, VIII, VII, V, and IV are essential for the initiation of coagulation. Proteins C and S inhibit the coagulation cascade by inactivating factors Va and VIIIa, respectively.

Sources

  1. "Medical Physiology" Elsevier (2016)
  2. "Physiology" Elsevier (2017)
  3. "Human Anatomy & Physiology" Pearson (2018)
  4. "Principles of Anatomy and Physiology" Wiley (2014)
  5. "Contact system revisited: an interface between inflammation, coagulation, and innate immunity" J Thromb Haemost (2016)
  6. "Thrombus formation in vivo" Journal of Clinical Investigation (2005)
  7. "Remodeling the Blood Coagulation Cascade" Journal of Thrombosis and Thrombolysis (2003)